Navigation Links
First 10-year follow-up shows that treatment with AVONEX leads to long-term benefits in early multiple sclerosis patients
Date:4/30/2009

SEATTLE, WA April 30, 2009 Biogen Idec (NASDAQ: BIIB) today announced data results from the CHAMPIONS (Controlled High-Risk AVONEX (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic Surveillance) study, an open label follow-up to CHAMPS (Controlled High Risk Subjects AVONEX MS Prevention Study). Based on the CHAMPS study, AVONEX was granted approval for use in patients who experienced their first clinical MS episode with MRI findings. The CHAMPIONS ten-year follow up showed that patients treated immediately after their first episode had significantly less chance of experiencing a second attack versus those patients with delayed treatment. These results at ten years also indicate that 80 percent of patients taking AVONEX were below an expanded disability status scale (EDSS) score of three. These data were presented as a poster at the Annual American Academy of Neurology (AAN) meeting.

"There is a consensus among physicians that early initiation of effective therapy beginning shortly after symptom onset may be required to alter the long term course of MS, but until now there has been little evidence to support this hypothesis," said Dr. R. Philip Kinkel, director of the multiple sclerosis center, Beth Israel Deaconess Medical Center in Boston, MA and lead investigator of CHAMPIONS. "This data confirms that treatment of high risk patients beginning shortly after symptom-onset reduces relapse rates and may reduce disease progression for up to 10 years. This may translate into an ability to remain active and enjoy daily activities that otherwise might be lost without treatment."

The CHAMPIONS open label follow-up study was designed to determine long-term clinical outcomes and the ten-year follow up included 155 patients from 24 of the 50 Phase III CHAMPS study sites. Key findings include:

  • 40 percent reduction in conversion to CDMS in patients treated immediately upon diagnosis of CIS versus those that were delayed by a median of 30 months (original placebo randomization arm)
  • 91 percent of patients had an EDSS less than 4.0 after 10 years;
  • 80 percent of patients on AVONEX had an EDSS of less than 3; and
  • the annualized relapse rate for patients with up to 10 years of care was only 0.25, suggesting a relapse rate of only one relapse every four years

"The CHAMPIONS study adds to the long-term follow-up data available and supports the benefits of starting early and staying on treatment with AVONEX," said Thorsten Eickenhorst, M.D., vice president of global medical affairs, Biogen Idec. "This follow-up study conducted in MS patients who received early treatment reinforces the clinical effectiveness of AVONEX in patients who experience their first clinical MS episode."


'/>"/>

Contact: Kathy Vigneault
kathleen.vigneault@mslworldwide.com
617-937-2546
Manning Selvage & Lee
Source:Eurekalert

Related medicine news :

1. First biomarker discovered that predicts prostate cancer outcome
2. FDA Approves First Anti-Psychotic for Kids
3. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
4. First study examines newly-licensed RN work attitudes and intentions
5. Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
8. High and mighty: first common height gene identified by researchers behind obesity gene finding
9. APA Comments on FDAs First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
10. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
11. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... 2017 , ... During the last week of March, Chad Kawa, MD of ... in the local community. , Colon cancer is the second leading cause of ... while it is small, confined and easier to treat. If you are 50 or ...
(Date:3/29/2017)... ... 2017 , ... In the United States alone, up to 36% of primary ... of metastatic brain tumors(3). Though most meningiomas are benign, metastatic brain tumors are known ... effective treatment options, the San Diego Gamma Knife Center offers a precision-medicine ...
(Date:3/29/2017)... ... March 29, 2017 , ... Full Contact K9, an Atlanta-based ... Pet Protect Law that assists dog owners in creating legally-enforceable pet trusts for ... taking the natural next step to protect their new companion. Says Evan Dunbar, CEO ...
(Date:3/29/2017)... ... March 30, 2017 , ... CHARM CITY RUN WELCOMES ... has announced that Mercy Medical Center will serve as the official title sponsor of ... On Sunday, June 25, 2017, thousands of women will walk or run the course ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its founder, Kathy ... "Wonder Spice", it has been used for thousands of years. , "The West has ... author of " Turmeric: How to Use it For Your Wellness. Overcome Inflammation, Enemy ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017  Zynex (OTCQB: ZYXI), an innovative ... of non-invasive medical devices for pain management, stroke rehabilitation, ... will host the Company,s 2016 full-year investor webcast on Monday, ... The Company expects to file its 2016 ... ...
(Date:3/29/2017)... , March 29, 2017 According to a new ... Type (Gas-Filled Detectors, Geiger Muller, Survey Meter, Solid-State), Products (Personal Dosimeters, OSL, ... 2021" published by MarketsandMarkets, the market is expected to reach USD 1,215.4 ... of 6.5% from 2016 to 2021. Continue ... ...
(Date:3/29/2017)... WASHINGTON , March 29, 2017  The Pharmaceutical ... regarding a new PhRMA report on patient out-of-pocket spending: ... for Medicare and Medicaid Services (CMS), the average amount ... be 13% of drug spending in 2016, down from ... is a pricing problem, not a coverage problem. Health ...
Breaking Medicine Technology: